Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2007 Jan;46(1):39-42.

[The efficacy and safety of tulobuterol tape in mild and moderate persistent asthma patients]

[Article in Chinese]
Nan Su  1 , Jiang-tao Lin, Meng Yang, Xin Chen, Jie He, Quan-ying He, Zhao-Long Cao, Bao-yuan Chen, Yi Xiao, Xi-xin Yan
Affiliations
  • PMID: 17331388
Randomized Controlled Trial

[The efficacy and safety of tulobuterol tape in mild and moderate persistent asthma patients]

[Article in Chinese]
Nan Su et al. Zhonghua Nei Ke Za Zhi. 2007 Jan.

Abstract

Objective: To evaluate the efficacy and safety of tulobuterol tape in mild and moderate persistent asthma patients.

Methods: A multicenter, randomized, controlled, open label study was performed. A total of 233 adult patients with mild and moderate persistent asthma were enrolled, and 115 patients were treated with tulobuterol tape and 118 with tulobuterol tablet.

Result: After 4 weeks of treatment, the morning peak expiratory flow (PEF) and evening PEF and the percent change in the tulobuterol tape group were increased significantly as compared to the tulobuterol tablet group (P < 0.05). The rate of improvement in morning PEF with the tape group and the tablet group were 9.1 (0.38 approximately 19.4)% and 4.2 (-6.4 approximately 18.3)%, respectively. The pulmonary function, variation rate of PEF, asthma score and usage of short-acting beta(2) agonist were improved after 4 weeks of treatment, but the differences were not significant between the two groups. The incidence of adverse reactions including palpitations and tremor in the tulobuterol tape group was significantly lower than that in the tablet group (chi(2) = 7.0919, P = 0.0077), and the incidence of local skin adverse reactions in tape group was 2.6%.

Conclusion: Tulobuterol tape is a newly formulated, effective and safe medication for the treatment of asthma.

PubMed Disclaimer